Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...

Terence Flynn has given his Buy rating due to a combination of factors that highlight Intellia Therapeutics’ promising clinical data and competitive positioning in the market. The recent updates from ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

Ken Hawkins, a retired teacher from Grants Pass, is first Oregon participant in phase 3 clinical trial Ken Hawkins, a 77-year ...

As BridgeBio approaches its FDA target date for approval of TTR stabilizer acoramidis to treat the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM), the company has presented more ...

In one of the most close­ly-watched are­nas in biotech, In­tel­lia says its gene edit­ing treat­ment for a heart mus­cle ...

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

Super Micro Computer, Inc. SMCI gained 11.1% to $20.64 in pre-market trading after gaining more than 3% on Friday. Fly-E ...

Latest news on the coronavirus, which has killed millions during a global pandemic.